Elan Corporation

21st December 2007

Elan and Wyeth Dose First Patient in North America in Phase 3 Program for Bapineuzumab (AAB-001) in Alzheimer's Disease

21st December 2007

Elan and Transition Therapeutics Dose First Patient in Phase 2 Clinical Study of ELND005 (AZD-103) in Alzheimer's Disease

18th December 2007

Elan to Present at the 26th Annual JP Morgan Healthcare Conference

12th December 2007

Elan Update

16th November 2007

CHMP Adopts Negative Opinion on Appeal on European Application For natalizumab for the Treatment of Crohn's Disease

29th October 2007

Elan Announces the Johnson & Johnson Pharmaceutical Research & Development Submission of a New Drug Application to the FDA for Paliperidone Palmitate Using Elan's Proprietary NanoCrystal® Technology

25th October 2007

Elan Reports Third Quarter 2007 Financial Results

15th October 2007

Elan Update

15th October 2007

Elan and Biogen Idec Announce That FDA Will Extend Regulatory Review Period for TYSABRI® for Crohn's Disease

11th October 2007

New TYSABRI® Data to Be Presented at the European Committee for Treatment and Research in Multiple Sclerosis

11th October 2007

Biogen Idec and Elan Provide Update on Utilization and Safety of TYSABRI® in Patients with Multiple Sclerosis

9th October 2007

Elan Announces Webcast of Third Quarter 2007 Financial Results

20th August 2007

TYSABRI® Demonstrates Significant Health-Related Quality-of-Life Improvements for Multiple Sclerosis Patients in Study Published in Annals of Neurology

14th September 2007

Elan Announces New Board of Director Members

9th August 2007

Dr. Lars Ekman, President of Research and Development, Transitions to Board of Director Role

31st July 2007

Joint FDA Advisory Committee Recommends Approval of TYSABRI® for the Treatment of Moderate to Severe Crohn's Disease

26th July 2007

Elan Reports Second Quarter 2007 Financial Results

23rd July 2007

TYSABRI® Celebrates One-Year Anniversary as a Treatment for Multiple Sclerosis

19th July 2007

Elan and Biogen Idec Preparing to Appeal Ruling on European Application for Natalizumab for the Treatment of Crohn's Disease

9th July 2007

Elan Announces Webcast of Second Quarter 2007 Financial Results

2nd July 2007

TYSABRI® Recommended by NICE for Use in Highly Active Relapsing Remitting Multiple Sclerosis in the Final Appraisal Determination

29th May 2007

Elan and Biogen Idec Announce a FDA Advisory Committee Meeting to Review TYSABRI®: for the Treatment of Crohn's Disease

24th May 2007

Elan to Present at the Goldman Sachs 28th Annual Global Healthcare Conference

24th May 2007

Elan Holds Its AGM, All Resolutions Passed

21st May 2007

Elan and Wyeth to Initiate Phase 3 Clinical Trial of Bapineuzumab (AAB-001) in Alzheimer's Disease

3rd May 2007

Data Presented at the American Academy of Neurology's Annual Meeting Provide Update on Utilization and Safety of TYSABRI® in Patients with Multiple Sclerosis

24th April 2007

Elan Reports First Quarter 2007 Financial Results

10th April 2007

Elan Announces Commencement of Exchange Offer for US$615 Million Aggregate Principal Amount of Notes

10th April 2007

Elan Announces Board of Director Changes

30th March 2007

Elan Announces Dates for Upcoming Corporate Events and Filing of Annual Report for Year Ended December 31, 2006

6th March 2007

Elan Announces Webcast of Presentation at the Cowen and Company 27th Annual Healthcare Conference

20th February 2007

Elan Reports Fourth Quarter and Full-Year 2006 Financial Results

22nd January 2007

Elan Announces Webcast of Fourth Quarter and Full Year 2006 Financial Results